Barclays
DMRA

Barclays’s Damora Therapeutics DMRA Stock Holding History

Barclays’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$274K Sell
10,525
-11,509
-52% -$279K ﹤0.01% 3537
2026
Q1 		$571K Buy
+22,034
New +$566K ﹤0.01% 3115
2025
Q4 		– Sell
-55
Closed -$205 – 5397
2025
Q3 		$205 Sell
55
-45
-45% -$152 ﹤0.01% 5241
2025
Q2 		$341 Sell
100
-33
-25% -$98 ﹤0.01% 5087
2025
Q1 		$412 Buy
+133
New +$627 ﹤0.01% 5091

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Barclays's DMRA Position: Q2 2026 in Review

Barclays reduced its Damora Therapeutics (DMRA) stake by 52% in Q2 2026, selling an estimated $279K and leaving 10,525 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #3537.

Barclays first reported a position in DMRA in Q1 2025 and has held it in 5 quarters since. The position peaked at $571K in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Barclays held 10,525 shares of Damora Therapeutics worth $274K as of Q2 2026.
  • Barclays sold 11,509 Damora Therapeutics shares in Q2 2026, an estimated $279K.
  • Damora Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3537 holding.
  • Barclays first reported a position in Damora Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Barclays's Damora Therapeutics position peaked at $571K in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.